Article

Pharmaceutical Executive

The Fundamental Disconnect Between Pharma and Technology

Author(s):

Michelle Maskaly

Otsuka Pharmaceutical’s President and CEO of Development and Commercialization William Carson explains the initial growing pains the company went through with their technology company partner in the early development stages of the first U.S. FDA approved digital medicine system.

Otsuka Pharmaceutical’s President and CEO of Development and Commercialization William Carson explains the initial growing pains the company went through with their technology company partner in the early development stages of the first U.S. FDA approved digital medicine system, Abilify Mycite.

His interview was recorded during the May 2018 Financial Times Live ‘s US Healthcare & Life Sciences Summit in New York City.

 

 

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Related Content
GAIN Therapeutics Ramps Up for Next Big Step in Parkinson’s Drug Development
August 4th 2025

GAIN Therapeutics Ramps Up for Next Big Step in Parkinson’s Drug Development

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, outlines how early trial results for GT-02287 are shaping the company’s strategy for advancing a potential new treatment for Parkinson’s disease.
Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement
August 4th 2025

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.
Credit: Shuo | stock.adobe.com
August 4th 2025

Six Essential Priorities for Life Sciences Chief Information Officers

Alister Campbell
Organizations commonly navigate outdated systems that make collaboration harder and breakthroughs slower, causing delays, missed insights, and costly rework.
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 4th 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Gaugarin Oliver
August 4th 2025

Navigating Uncertainty with AI: Building Trust in the Way Forward

Gaugarin Oliver
Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.
Zifo Survey Shows Biopharma Racing Toward AI Despite Data Management Challenges
August 4th 2025

Zifo Survey Shows Biopharma Racing Toward AI Despite Data Management Challenges

Don Tracy, Associate Editor
A global survey of scientists and informaticians reveals growing AI investment across the biopharma value chain, but highlights gaps in data integration, standardization, and infrastructure that threaten to stall progress.